Literature DB >> 29735439

[Estradiol significantly increases the expression of antioxidant enzymes in osteoporotic rats and osteoblasts in vitro].

Xue-Juan Zhou1, Ying Xia, Yan-Yan Zhao, Wen-Qing Gu, Xiao Xiao, Xiao-Chun Bai, Jun Liu, Ming Li.   

Abstract

OBJECTIVE: To investigate the effect of estradiol on the expression of antioxidant enzymes in osteoblasts and its role in postmenopausal osteoporosis.
METHODS: Rat models of osteoporosis established by ovariectomy were treated with estradiol for 3 months, and the changes in serum levels of reactive oxygen species (H2O2) and antioxidant enzymes (γ -GCS, GSH-ST and GSH-px) were detected. The effects of estradiol on the expression of γ -GCS mRNA and protein in osteoblast-like cells MC3T3-E1, MG63 and OB were examined with PCR and Western blotting. Using a mRNA microarray, we analyzed the changes in the expressions of 84 antioxidant enzymes in the osteoblast cell line MC3T3-E1 following estradiol treatment, and the enzymes with significant changes were verified by PCR. CCK-8 kit was used to evaluate the effect of estradiol and antioxidant NAC on the proliferation of MC3T3-E1 cells.
RESULTS: Rat models of osteoporosis were successfully established with ovariectomy. The osteoporotic rats showed significantly increased serum level of reactive oxygen species (H2O2) and decreased levels of antioxidant enzymes. Estrogen treatment of the osteoporotic rats obviously reversed the phenotype of osteoporosis, lowered serum level of reactive oxygen species, and increased the level of γ -GCS. In MC3T3-E1, MG63 and OB cells, estradiol treatment significantly upregulated the expression levels of γ -GCS mRNA and protein. In MC3T3-E1 cells treated with estrogen, the mRNA chip identified 6 upregulated antioxidant enzymes (Gpx6, Gstk1, Nos2, Prdx2, Ngb and Ccs), and the results of PCR verified that estradiol upregulated Ccs and Ngb mRNAs in MC3T3-E1, MG63 and OB cells. Estradiol and antioxidant NAC obviously promoted the proliferation of MC3T3-E1 cells.
CONCLUSION: Estradiol significantly increases the expression of antioxidase γ -Gcs, Ccs and Ngb in osteoblasts in vitro. Postmenopausal osteoporosis is closely related with the increase of reactive oxygen species and the decrease of antioxidant levels. In osteoblasts, estrogen deficiency may increase the level of reactive oxygen species, decrease the level of antioxidant enzymes, activate the oxidative stress cascade, and consequently inhibit the proliferation of osteoblasts to aggravate the condition of osteoporosis.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29735439      PMCID: PMC6765658     

Source DB:  PubMed          Journal:  Nan Fang Yi Ke Da Xue Xue Bao        ISSN: 1673-4254


  13 in total

1.  Therapeutic effect of deferoxamine on iron overload-induced inhibition of osteogenesis in a zebrafish model.

Authors:  Bin Chen; Yi-Lin Yan; Chen Liu; Lin Bo; Guang-Fei Li; Han Wang; You-Jia Xu
Journal:  Calcif Tissue Int       Date:  2014-01-12       Impact factor: 4.333

Review 2.  Physiology of bone loss.

Authors:  Bart L Clarke; Sundeep Khosla
Journal:  Radiol Clin North Am       Date:  2010-05       Impact factor: 2.303

Review 3.  Superoxide dismutases: role in redox signaling, vascular function, and diseases.

Authors:  Tohru Fukai; Masuko Ushio-Fukai
Journal:  Antioxid Redox Signal       Date:  2011-06-06       Impact factor: 8.401

4.  Effects of Chronic Estrogen Administration in the Ventromedial Nucleus of the Hypothalamus (VMH) on Fat and Bone Metabolism in Ovariectomized Rats.

Authors:  Z Zhang; J Liu; A G Veldhuis-Vlug; Y Su; E Foppen; B C J van der Eerden; M Koedam; N Bravenboer; A Kalsbeek; A Boelen; E Fliers; P H Bisschop
Journal:  Endocrinology       Date:  2016-10-24       Impact factor: 4.736

5.  A crucial role for thiol antioxidants in estrogen-deficiency bone loss.

Authors:  Jenny M Lean; Julie T Davies; Karen Fuller; Christopher J Jagger; Barrie Kirstein; Geoffrey A Partington; Zoë L Urry; Timothy J Chambers
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

6.  Iron overload causes osteoporosis in thalassemia major patients through interaction with transient receptor potential vanilloid type 1 (TRPV1) channels.

Authors:  Francesca Rossi; Silverio Perrotta; Giulia Bellini; Livio Luongo; Chiara Tortora; Dario Siniscalco; Matteo Francese; Marco Torella; Bruno Nobili; Vincenzo Di Marzo; Sabatino Maione
Journal:  Haematologica       Date:  2014-09-12       Impact factor: 9.941

7.  The antioxidant effect of estrogen and Selective Estrogen Receptor Modulators in the inhibition of osteocyte apoptosis in vitro.

Authors:  Val Mann; Christene Huber; Giolanta Kogianni; Frances Collins; Brendon Noble
Journal:  Bone       Date:  2006-12-13       Impact factor: 4.398

Review 8.  Trigeminal neuralgia: New classification and diagnostic grading for practice and research.

Authors:  Giorgio Cruccu; Nanna B Finnerup; Troels S Jensen; Joachim Scholz; Marc Sindou; Peter Svensson; Rolf-Detlef Treede; Joanna M Zakrzewska; Turo Nurmikko
Journal:  Neurology       Date:  2016-06-15       Impact factor: 9.910

9.  A Jak1/2 inhibitor, baricitinib, inhibits osteoclastogenesis by suppressing RANKL expression in osteoblasts in vitro.

Authors:  Kohei Murakami; Yasuhiro Kobayashi; Shunsuke Uehara; Takako Suzuki; Masanori Koide; Teruhito Yamashita; Midori Nakamura; Naoyuki Takahashi; Hiroyuki Kato; Nobuyuki Udagawa; Yukio Nakamura
Journal:  PLoS One       Date:  2017-07-14       Impact factor: 3.240

10.  Stereological investigation of the effect of Elaeagnus angustifolia fruit hydroalcoholic extract on osteoporosis in ovariectomized rats.

Authors:  Mohmmad Hossein Dabbaghmanesh; Ali Noorafshan; Pedram Talezadeh; Nader Tanideh; Farhad Koohpeyma; Aida Iraji; Marzieh Bakhshayeshkaram; Nima Montazeri-Najafabady
Journal:  Avicenna J Phytomed       Date:  2017 May-Jun
View more
  1 in total

1.  Peroxiredoxin II negatively regulates BMP2-induced osteoblast differentiation and bone formation via PP2A Cα-mediated Smad1/5/9 dephosphorylation.

Authors:  Kyeong-Min Kim; Do-Young Kim; Dong-Seok Lee; Jung-Woo Kim; Jeong-Tae Koh; Eun-Jung Kim; Won-Gu Jang
Journal:  Exp Mol Med       Date:  2019-06-03       Impact factor: 8.718

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.